Authors
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Radical nephrectomy before or after systemic therapy for mRCCRecent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Latest:
How text messaging can be a valuable tool for your practiceHere are seven ways texting can improve healthcare revenue and decrease costs.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Abemaciclib trial misses end point, but supports targeting CDK4/6 in mCRPCThe CDK4/6 inhibitor abemaciclib showed clinically activity in patients with heavily pretreated metastatic castration-resistant prostate cancer.
Latest:
Managing your online reputation in health careWhile online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Latest:
Neoadjuvant chemoimmunotherapy combo shows promise in UTUCThe phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Latest:
University Hospitals Cleveland Medical Center named first SpaceOAR Hydrogel Center of ExcellenceThe device helps reduce unintentional side effects of prostate cancer therapy.
Latest:
Allina Health Cancer Institute 2022 Symposium reimagines cancer careThe symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Abiraterone-based triplet boosts survival in de novo mCSPCFindings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest:
Why favor high intensity focused ultrasound for treating localized prostate cancer?"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Study signals benefit with maintenance darolutamide in mCRPCPatients in the trial received switch maintenance with darolutamide following prior taxane chemotherapy and at least 1 androgen-receptor pathway inhibitor.
Latest:
Expert advice on improving interactions with difficult patients“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Malpractice Consult: What you should know about jury selectionHere are some ways in which lawyers can remove potential jurors from a case.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Bladder-sparing trimodal therapy yields similar results as radical cystectomy in MIBCThe 5-year metastasis-free survival rate was 75% with trimodality therapy vs 74% with radical cystectomy.
Latest:
UCSF Department of Urology Grand Rounds with Dr. Ezekiel J. Emanuel: October 14Join the discussion on Health Reform with world leader in health policy and bioethics, Ezekiel J. Emanuel, MD, PhD, the Vice Provost for Global Initiatives and expert panelists and UCSF leaders.
Latest:
How to perform office-based blue light cystoscopyBLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
Transurethral resection of the bladder tumor: Standard technique and new advancementsImprovement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Expert shares key cybersecurity fundamentals and best practicesCybersecurity training is vital because it is mandated by HIPAA.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
